Dr. David Maberley MD, FRCS(C), MSc joins Medical Advisor Board of Canadian Bio Med Systems Inc.

NEW YORK, MONTREAL, SAN DIEGO, May 24 /PRNewswire-FirstCall/ - Canadian Bio Med Systems Inc., a subsidiary of ICBS Ltd., (OTCPK: ICBT), and Ocular Therapeutics Inc., of San Diego California, announced today that Dr David Maberley, of the Department of Ophthalmology The University of British Columbia has joined the Medical Advisory Board of CBMS.

David Maberley MD, FRCS(C), MSc is the director of the Vancouver Native Health Society's Eye Clinic. Dr. Maberley sits on the Board of Directors of the .

Canadian Ophthalmology Society and is also on the Diabetic Retinopathy Guidelines Committee . He has written Surgical and medical management of proliferative diabetic retinopathy; Cost-effectiveness of screening and treatment; Management of PDR and CSME; Management of ischemic maculopathy. Head of Vitreoretinal section of Canadian Ophthalmology Society. Dr. Maberley is ophthalmic director of the BC On-reserve Telemedicine ProjectConsultant for VIHA Teleophthalmology Program and is editor (retina) for Canadian Journal of Ophthalmology.

Commenting on the latest member of the Medical Advisory Board, Dr. George Tsoukas, Medical Director (CBMS), says "Dr. Maberley is a major asset to help direct our efforts in solving the problems of Age-related Macular degeneration.. His experience will add greatly to our ability to move forward."

Age-Related Macular Degeneration (AMD) is the leading cause of blindness, worldwide, for people over 55 years of age. The incidence of AMD in persons aged 55 is 1% and increases to 15% for persons aged 80. This debilitating disease has proven to be difficult to treat and only a very few drugs have been developed which have positive effects.

The drug under development by Canadian Bio Med Systems , has a very different mode of action than the current therapeutic products. It can be used alone or in conjunction with these currently available products.

The product under development by CBMS, LD22-4 has the advantage of being a very small molecule meaning that fewer treatments will be needed compared to current therapies, This will help reduce the pain and frequency of injection to the patient and potentially the cost of the treatment.

Canadian Bio Med is developing the new product in Montreal in conjunction with its partner, Ocular Therapeutics Inc. of San Diego, California. The drug is moving toward human clinical trials in Canada and the United States next year.

Canadian Bio Med Systems Inc., and Ocular Therapeutics Inc. of San Diego California, has acquired the licensing rights to two new potentially revolutionary drugs in the billion dollar ophthalmic arena .

The drug for the treatment of glaucoma is being developed by Daniel Stamer, PhD and Ronald Heimark, PhD at the University of Arizona. Glaucoma is a prevalent eye disease is one of the leading causes of blindness in the world. Patient compliance is a serious problem in glaucoma because of the frequency which conventional medication is required. The new drug being developed may change the paradigm of glaucoma therapy.

Eugene Levin, PhD at Torrey Pines in San Diego, California is developing the new drug for age-related macular degeneration (AMD). The protein in this compound is derived from a larger, naturally occurring human protein which will be used to control dangerous vessel growth in the retina at the very back of the eye. The new drug being developed is a much smaller protein than other AMD drugs being used today which means it may be used less frequently.

NB. This news release includes statements that constitute forward-looking statements. Please be aware that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may vary materially from those in the forward-looking statements as a result of any number of factors, including the risk factors contained in the Company's disclosure documents.

SOURCE Inter Canadian Business Service